ReviewCancer immunology, immunotherapy : CII2013
Circulating tumor cells as therapy-related biomarkers in cancer patients.
Review in Cancer immunology, immunotherapy : CII, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The prognostic role of circulating tumor cells in gastric cancer: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer.Cancer immunology, immunotherapy : CII · 2018Trial
- Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer.Cancer immunology, immunotherapy : CII · 2015Trial
- Analyzed PD-L1-positive subpopulations by dual-labeling TSA-IF-FISH predicts immunotherapy efficacy in advanced lung cancer.iScience · 2026Article
- The prospects and limitations of liquid biopsy utilization for clinical practice in Taiwan.The journal of liquid biopsy · 2025Article
- Review
- Impact of Local Anesthetics on Cancer Behavior and Outcome during the Perioperative Period: A Review.Medicina (Kaunas, Lithuania) · 2022Review
- Article
- Toward a New Era for the Management of Circulating Tumor Cells.Advances in experimental medicine and biology · 2021Review
- Future perspectives from lung cancer pre-clinical models: new treatments are coming?Translational lung cancer research · 2020Review
- Past, Present, and Future of Affinity-based Cell Separation Technologies.Acta biomaterialia · 2020Review
- Article
- Detection of Androgen Receptor Variant 7 (Cells · 2019Article
- Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects.Cancers · 2019Review
- Detection of circulating tumor cells in blood by shell-isolated nanoparticle - enhanced Raman spectroscopy (SHINERS) in microfluidic device.Scientific reports · 2019Article
- Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.International journal of colorectal disease · 2019Article
- Detection of Circulating Tumor Cells Using Membrane-Based SERS Platform: A New Diagnostic Approach for 'Liquid Biopsy'.Nanomaterials (Basel, Switzerland) · 2019Article
- Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.Yonsei medical journal · 2018Article
- Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells.Cancer letters · 2017Article
- SIDEseq: A Cell Similarity Measure Defined by Shared Identified Differentially Expressed Genes for Single-Cell RNA sequencing Data.Statistics in biosciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinomas (tumors of epithelial origin) are responsible for most of all new cancers in the industrialized countries. Due to the high mortality rate caused by the metastatic spread of aggressive cancer cells, there is an urgent demand in finding new biomarkers, which should detect early formation of metastases and monitor efficacy of systemic adjuvant therapy in a timely manner. It has been considered that the molecular analysis of cells which are shed from tumors into the blood system (circulating tumor cells (CTCs)) might provide new insights for the clinical management of cancer, probably far earlier than using traditional high-resolution imaging technologies. Clinical trials indicated that CTCs can be deployed for diagnostic, monitoring, and prognostic purposes. Furthermore, these cells are discussed to be suitable as predictive markers. In any case, identification of CTCs requires innovative and challenging technologies as detection methods should be specific, sensitive, standardized, and highly reproducible. Although many different approaches have been developed until now, only the CellSearch™ method has been cleared by the American Food and Drug Administration. Although the detection of CTCs has already shown to have a prognostic impact in many tumor entities including breast, prostate, lung and colon cancer, ongoing and future studies are aimed to explore whether CTCs can be used for an individual therapy decision making including novel immunotherapeutic approaches. This review discusses (1) different detection strategies for CTCs, (2) their clinical impact, and (3) the potential use of CTCs guiding the treatment of individual cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.